Literature DB >> 33512385

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis.

Vandana Chaturvedi1, Rebecca A Marsh2, Adi Zoref-Lorenz1,3, Erika Owsley2, Vijaya Chaturvedi2, Trung C Nguyen4, Jordana R Goldman5, Michael M Henry6, Jay N Greenberg7, Stephan Ladisch7, Michelle L Hermiston8, Michael Jeng9, Ahmed Naqvi10, Carl E Allen11, Hector R Wong12, Michael B Jordan1,2.   

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a fatal disorder of immune hyperactivation that has been described as a cytokine storm. Sepsis due to known or suspected infection has also been viewed as a cytokine storm. Although clinical similarities between these syndromes suggest similar immunopathology and may create diagnostic uncertainty, distinguishing them is critical as treatments are widely divergent. We examined T-cell profiles from children with either HLH or sepsis and found that HLH is characterized by acute T-cell activation, in clear contrast to sepsis. Activated T cells in patients with HLH were characterized as CD38high/HLA-DR+ effector cells, with activation of CD8+ T cells being most pronounced. Activated T cells were type 1 polarized, proliferative, and displayed evidence of recent and persistent activation. Circulating activated T cells appeared to be broadly characteristic of HLH, as they were seen in children with and without genetic lesions or identifiable infections and resolved with conventional treatment of HLH. Furthermore, we observed even greater activation and type 1 polarization in tissue-infiltrating T cells, described here for the first time in a series of patients with HLH. Finally, we observed that a threshold of >7% CD38high/HLA-DR+ cells among CD8+ T cells had strong positive and negative predictive value for distinguishing HLH from early sepsis or healthy controls. We conclude that the cytokine storm of HLH is marked by distinctive T-cell activation whereas early sepsis is not, and that these 2 syndromes can be readily distinguished by T-cell phenotypes.
© 2021 by the American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33512385      PMCID: PMC8085480          DOI: 10.1182/blood.2020009499

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  43 in total

1.  Safety and efficacy of blinatumomab: a real world data.

Authors:  Arie Apel; Yishai Ofran; Ofir Wolach; Shai Shimony; Ron Ram; Itai Levi; Miri Zektser; Maya Koren-Michowitz
Journal:  Ann Hematol       Date:  2020-02-20       Impact factor: 3.673

2.  Massive expansion of EBV+ monoclonal T cells with CD5 down regulation in EBV-associated haemophagocytic lymphohistiocytosis.

Authors:  Ming-Tsan Lin; Hui-Mei Chang; Chang-Jen Huang; Woan-Ling Chen; Chi-Yung Lin; Ching-Yang Lin; Shih-Sung Chuang
Journal:  J Clin Pathol       Date:  2007-01       Impact factor: 3.411

3.  Down-regulation of CD5 expression on activated CD8+ T cells in familial hemophagocytic lymphohistiocytosis with perforin gene mutations.

Authors:  Taizo Wada; Yasuhisa Sakakibara; Ryosei Nishimura; Tomoko Toma; Yasuhisa Ueno; Seiki Horita; Taihei Tanaka; Masanori Nishi; Keisuke Kato; Takahiro Yasumi; Osamu Ohara; Akihiro Yachie
Journal:  Hum Immunol       Date:  2013-09-16       Impact factor: 2.850

Review 4.  Similar but not the same: Differential diagnosis of HLH and sepsis.

Authors:  Rafał Machowicz; Gritta Janka; Wieslaw Wiktor-Jedrzejczak
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-23       Impact factor: 6.312

5.  Immunophenotypic analysis of Epstein-Barr virus (EBV)-infected CD8(+) T cells in a patient with EBV-associated hemophagocytic lymphohistiocytosis.

Authors:  Taizo Wada; Toshiro Kurokawa; Tomoko Toma; Fumie Shibata; Yumi Tone; Yoko Hashida; Hiroyasu Kaya; Takashi Yoshida; Akihiro Yachie
Journal:  Eur J Haematol       Date:  2007-05-28       Impact factor: 2.997

Review 6.  Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes.

Authors:  Scott W Canna; Edward M Behrens
Journal:  Pediatr Clin North Am       Date:  2012-04       Impact factor: 3.278

7.  Trigger-dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis.

Authors:  Ruth Gather; Peter Aichele; Nadja Goos; Jan Rohr; Hanspeter Pircher; Tamara Kögl; Robert Zeiser; Hartmut Hengel; Annette Schmitt-Gräff; Casey Weaver; Stephan Ehl
Journal:  Eur J Immunol       Date:  2020-06-02       Impact factor: 5.532

8.  Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.

Authors:  Franco Locatelli; Michael B Jordan; Carl Allen; Simone Cesaro; Carmelo Rizzari; Anupama Rao; Barbara Degar; Timothy P Garrington; Julian Sevilla; Maria-Caterina Putti; Franca Fagioli; Martina Ahlmann; Jose-Luis Dapena Diaz; Michael Henry; Fabrizio De Benedetti; Alexei Grom; Genevieve Lapeyre; Philippe Jacqmin; Maria Ballabio; Cristina de Min
Journal:  N Engl J Med       Date:  2020-05-07       Impact factor: 91.245

Review 9.  Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO).

Authors:  Michael B Jordan; Carl E Allen; Jay Greenberg; Michael Henry; Michelle L Hermiston; Ashish Kumar; Melissa Hines; Olive Eckstein; Stephan Ladisch; Kim E Nichols; Carlos Rodriguez-Galindo; Birte Wistinghausen; Kenneth L McClain
Journal:  Pediatr Blood Cancer       Date:  2019-07-24       Impact factor: 3.167

10.  COVID-19: consider cytokine storm syndromes and immunosuppression.

Authors:  Puja Mehta; Daniel F McAuley; Michael Brown; Emilie Sanchez; Rachel S Tattersall; Jessica J Manson
Journal:  Lancet       Date:  2020-03-16       Impact factor: 79.321

View more
  8 in total

1.  Protective Effect of Poria Cocos Polysaccharides on Fecal Peritonitis-Induced Sepsis in Mice Through Inhibition of Oxidative Stress, Inflammation, Apoptosis, and Reduction of Treg Cells.

Authors:  Yu Wu; Dai Li; Han Wang; Xiaojian Wan
Journal:  Front Microbiol       Date:  2022-05-27       Impact factor: 6.064

2.  CD8 + T Cells Exhibit an Exhausted Phenotype in Hemophagocytic Lymphohistiocytosis.

Authors:  Madhura G Kelkar; Umair Ahmad Bargir; Reetika Malik-Yadav; Maya Gupta; Aparna Dalvi; Neha Jodhawat; Shweta Shinde; Manisha R Madkaikar
Journal:  J Clin Immunol       Date:  2021-08-14       Impact factor: 8.317

Review 3.  Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?

Authors:  Johnson M Liu; Jeffrey Chi
Journal:  Exp Biol Med (Maywood)       Date:  2022-01-22

Review 4.  Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies.

Authors:  Halil Yildiz; Sarah Bailly; Eric Van Den Neste; Jean Cyr Yombi
Journal:  Ther Clin Risk Manag       Date:  2021-04-14       Impact factor: 2.423

5.  Distinguishing immune activation and inflammatory signatures of multisystem inflammatory syndrome in children (MIS-C) versus hemophagocytic lymphohistiocytosis (HLH).

Authors:  Deepak Kumar; Christina A Rostad; Preeti Jaggi; D Sofia Villacis Nunez; Chengyu Prince; Austin Lu; Laila Hussaini; Thinh H Nguyen; Sakshi Malik; Lori A Ponder; Sreekala P V Shenoy; Evan J Anderson; Michael Briones; Ignacio Sanz; Sampath Prahalad; Shanmuganathan Chandrakasan
Journal:  J Allergy Clin Immunol       Date:  2022-03-15       Impact factor: 14.290

Review 6.  Targeting CD38 in Neoplasms and Non-Cancer Diseases.

Authors:  Wojciech Szlasa; Jakub Czarny; Natalia Sauer; Katarzyna Rakoczy; Natalia Szymańska; Jakub Stecko; Maksymilian Kołodziej; Maciej Kaźmierczak; Ewa Barg
Journal:  Cancers (Basel)       Date:  2022-08-28       Impact factor: 6.575

Review 7.  Improving Diagnosis and Clinical Management of Acquired Systemic Autoinflammatory Diseases.

Authors:  Adam Al-Hakim; Anoop Mistry; Sinisa Savic
Journal:  J Inflamm Res       Date:  2022-10-10

8.  Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy.

Authors:  Melissa R Hines; Camille Keenan; Gabriela Maron Alfaro; Cheng Cheng; Yinmei Zhou; Akshay Sharma; Caitlin Hurley; Kim E Nichols; Stephen Gottschalk; Brandon M Triplett; Aimee C Talleur
Journal:  Br J Haematol       Date:  2021-07-15       Impact factor: 6.998

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.